Clinical-genetic model predicts incident impulse control disorders in Parkinson's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 10, 2016, Pages 1106-1111

  Kraemmer, Julia ^{a,b,c,d,e,f,g}   Smith, Kara ^h   Weintraub, Daniel ^h,i   Guillemot, Vincent ^a,b,c,d,e,f   Nalls, Mike A ^j   Cormier Dequaire, Florence ^a,b,c,d,e,f   Moszer, Ivan ^a,b,c,d,e,f   Brice, Alexis ^a,b,c,d,e,f   Singleton, Andrew B ^j   Corvol, Jean Christophe ^a,b,c,d,e,f  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c CIC 1422   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e ICM   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g MEDICAL UNIVERSITY OF VIENNA   (Austria)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; SEROTONIN TRANSPORTER; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ADRA2C GENE; AGED; ARTICLE; COHORT ANALYSIS; COMT GENE; CONTROLLED STUDY; DAT1 GENE; DDC GENE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRD2 GENE; DRD3 GENE; FEMALE; FOLLOW UP; GENE; GENETIC MODEL; GENETIC VARIABILITY; GENOTYPE; GRIN2B GENE; HTR2A GENE; HUMAN; IMPULSE CONTROL DISORDER; MAJOR CLINICAL STUDY; MALE; OPRK1 GENE; OPRM1 GENE; PARKINSON DISEASE; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SERT GENE; TPH2 GENE; WHOLE EXOME SEQUENCING; BIOLOGICAL MODEL; CHEMICALLY INDUCED; CLINICAL TRIAL; DISABILITY; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DNA SEQUENCE; EXOME; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ANTIPARKINSON AGENTS; DISABILITY EVALUATION; DISRUPTIVE, IMPULSE CONTROL, AND CONDUCT DISORDERS; DOPAMINE AGENTS; EXOME; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, GENETIC; MULTIVARIATE ANALYSIS; PARKINSON DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84964573499     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-312848     Document Type: Article

References (41)

1. Grant JE, Atmaca M, Fineberg NA, et al. Impulse control disorders and "behavioural addictions" in the ICD-11. World Psychiatry 2014;13:125-7.
2. Weintraub D, Papay K, Siderowf A, Parkinson's Progression Markers I. Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology 2013;80:176-80.
3. Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord 2015;30:121-7.
4. Antonini A, Siri C, Santangelo G, et al. Impulsivity and compulsivity in drug-naive patients with Parkinson's disease. Mov Disord 2011;26:464-8.
5. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67:589-95.
6. Bastiaens J, Dorfman BJ, Christos PJ, et al. Prospective cohort study of impulse control disorders in Parkinson's disease. Mov Disord 2013;28:327-33.
7. Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case - control study. Ann Neurol 2011;69:986-96.
8. Phu AL, Xu Z, Brakoulias V, et al. Effect of impulse control disorders on disability and quality of life in Parkinson's disease patients. J Clin Neurosci 2014;21:63-6.
9. Joutsa J, Martikainen K, Vahlberg T, et al. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2012;18:1079-83.
10. Hurt CS, Alkufri F, Brown RG, et al. Motor phenotypes, medication and mood: further associations with impulsive behaviours in Parkinson's disease. J Parkinsons Dis 2014;4:245-54.
11. Weintraub D. Impulse control disorders in Parkinson's disease: prevalence and possible risk factors. Parkinsonism Relat Disord 2009;15(Suppl 3):S110-3.
12. Valença GT, Glass PG, Negreiros NN, et al. Past smoking and current dopamine agonist use show an independent and dose-dependent association with impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord 2013;19:698-700.
13. Eisen SA, Lin N, Lyons MJ, et al. Familial influences on gambling behavior: an analysis of 3359 twin pairs. Addiction 1998;93:1375-84.
14. Slutske WS, Zhu G, Meier MH, et al. Genetic and environmental influences on disordered gambling in men and women. Arch Gen Psychiatry 2010;67:624-30.
15. Brewer JA, Potenza MN. The neurobiology and genetics of impulse control disorders: relationships to drug addictions. Biochem Pharmacol 2008;75:63-75.
16. Napier TC, Corvol JC, Grace AA, et al. Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease. Mov Disord 2015;30:141-9.
17. Cormier F, Muellner J, Corvol JC. Genetics of impulse control disorders in Parkinson's disease. J Neural Transm (Vienna) 2013;120:665-71.
18. Kim YE, Jeon BS. Genetic susceptibility of impulse control and related behavior in Parkinson's disease. J Parkinsons Dis 2014;4:261-72.
19. Lee JY, Lee EK, Park SS, et al. Association of DRD3 and GRIN2B with impulse control and related behaviors in Parkinson's disease. Mov Disord 2009;24:1803-10.
20. Lee JY, Jeon BS, Kim HJ, et al. Genetic variant of HTR2A associates with risk of impulse control and repetitive behaviors in Parkinson's disease. Parkinsonism Relat Disord 2012;18:76-8.
21. Vallelunga A, Flaibani R, Formento-Dojot P, et al. Role of genetic polymorphisms of the dopaminergic system in Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord 2012;18:397-9.
22. Zainal Abidin S, Tan EL, Chan SC, et al. DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients. BMC Neurol 2015;15:59.
23. Nalls MA, Bras J, Hernandez DG, et al. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiol Aging 2015;36:1605.e7-12.
24. DePristo MA, Banks E, Poplin R, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011;43:491-8.
25. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
26. Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinform 2013;11:11 10 1-11 10 33.
27. Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2009;24:1461-7.
28. Chang CC, Chow CC, Tellier LC, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:7.
29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
30. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res 2000;126:325-41.
31. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002;283:R287-95.
32. Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav 2014;123:25-33.
33. Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 2012;69:857-96.
34. Wang SC, Tsou HH, Chung RH, et al. The association of genetic polymorphisms in the kappa-opioid receptor 1 gene with body weight, alcohol use, and withdrawal symptoms in patients with methadone maintenance. J Clin Psychopharmacol 2014;34:205-11.
35. Kumar D, Chakraborty J, Das S. Epistatic effects between variants of kappa-opioid receptor gene and A118G of mu-opioid receptor gene increase susceptibility to addiction in Indian population. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:225-30.
36. Galduroz JCF, Ramos AC, Santos-Galduroz RF, et al. Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study. Neurology 2015;84:1386-7.
37. Gray JC, MacKillop J. Genetic basis of delay discounting in frequent gamblers: examination of a priori candidates and exploration of a panel of dopamine-related loci. Brain Behav 2014;4:812-21.
38. Agrawal A, Verweij KJ, Gillespie NA, et al. The genetics of addiction-a translational perspective. Transl Psychiatry 2012;2:e140.
39. Ma JZ, Beuten J, Payne TJ, et al. Haplotype analysis indicates an association between the DOPA decarboxylase (DDC) gene and nicotine dependence. Hum Mol Genet 2005;14:1691-8.
40. Devos D, Lejeune S, Cormier-Dequaire F, et al. Dopa-decarboxylase gene polymorphisms affect the motor response to L-dopa in Parkinson's disease. Parkinsonism Relat Disord 2014;20:170-5.
41. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatr 2014;85:840-4.